For more than 145 years, we have worked tirelessly to develop and deliver trusted medicines and diagnostics that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neuroscience and obesity.

Learn the latest information on the availability of Lilly diabetes and obesity medicines. Learn how to protect yourself from counterfeit Mounjaro ® and Zepbound ® and unapproved tirzepatide …

Take the next step in your care journey with LillyDirect® for select Lilly medicines, independent virtual and in-person services, and online pharmacy solutions.

For more than 140 years, Eli Lilly and Company has worked tirelessly to develop and deliver trusted medicines that meet real needs. Learn more about Lilly's portfolio of medicines.

Dec 13, 2024 · Eli Lilly and Company manufactures, markets and/or distributes more than 52 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Upon verification, healthcare professionals have access to Eli Lilly product information and professional resources. Get answers to medical questions and access to Lilly scientific resources.

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh ... See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of ...

INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This unique facility will give Lilly the ability to research new ways of producing medicines, while also scaling up ...

INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...

INDIANAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein (a) [Lp (a)], a …